Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCAR7B)

• Drug Name: O-Sialic Acid Drug Info
• Synonyms: alpha-Neu5Ac; N-acetyl-alpha-neuraminic acid; O-sialic acid; CHEBI:49026; N-Acetyl-a-neuraminic acid; UNII-04A90EXP8V; sialic acid; 04A90EXP8V; N-acetyl-alpha-neuraminate; NANA; 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosonic acid; 131-48-6; SIA; (2R,4S,5R,6R)-5-acetamido-2,4-dihydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid; polysialic acid; Alpha-Sialoside; 4lkh; 2qwb; N-Acetyl-a-neuraminate; N-Acetyl-a-D-neuraminate; Epitope ID:136794; SCHEMBL79085; N-Acetyl-a-D-neuraminic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 444885
  ChEBI ID: CHEBI:49026
  CAS Number: CAS 21646-00-4
  TTD Drug ID: DMCAR7B

Molecule-Related Drug Atlas

Drug(s) Targeting P-selectin (SELP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizanlizumab	DMAHOVJ	Vaso-occlusive crisis	BE2Y	Approved	[2]
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[3]
Inclacumab	DMXV94M	Sickle-cell disorder	3A51	Phase 3	[4]
CY-1503	DML906E	Hypertension	BA00-BA04	Phase 2/3	[5]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[6]
SelG1	DMTQ2K0	Vaso-occlusive crisis	BE2Y	Phase 2	[7]
RPSGL-Ig	DM0BFJ5	Delayed graft function	4B24.0	Phase 2	[8]
PSI-697	DM75FWO	Atherosclerosis	BD40	Phase 1	[9]
CDP-850	DMWHQM3	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[10]
CY-1787	DMWY2NT	Allergy	4A80-4A85	Discontinued in Phase 1	[11]

Drug(s) Targeting Influenza Neuraminidase (Influ NA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oseltamivir	DMGO72P	Influenza	1E30-1E32	Approved	[12]
Zanamivir	DMFMBZ4	Influenza	1E30-1E32	Approved	[12]
Peramivir	DMNXY5K	Influenza virus infection	1E30-1E32	Approved	[13]
UX-001	DMD2O0L	Hereditary inclusion body myositis	4A41.2	Phase 3	[14]
CS-8958	DM4CSDH	Influenza virus infection	1E30-1E32	Phase 3	[13]
DAS-181	DM0Y8JP	Influenza virus infection	1E30-1E32	Phase 2	[15]
Lactose	DMO4GPK	Discovery agent	N.A.	Phase 1	[14]
GS-3435	DMV7JC6	Influenza virus infection	1E30-1E32	Terminated	[16]
BCX-140	DMBJERO	Influenza virus infection	1E30-1E32	Terminated	[17]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[14]

Drug(s) Targeting E-selectin (SELE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[3]
GMI-1271	DMDTGWQ	Acute myeloid leukaemia	2A60	Phase 3	[18]
CY-1503	DML906E	Hypertension	BA00-BA04	Phase 2/3	[5]
Bimosiamose	DM0TH9A	Atopic dermatitis	EA80	Phase 2a	[19]
GMI-1359	DML1KSA	Breast cancer	2C60-2C65	Phase 1	[20]
PF-07209326	DM7YRAL	Sickle-cell disorder	3A51	Phase 1	[21]
GI-270384X	DM3KN2Q	Inflammatory bowel disease	DD72	Terminated	[22]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[14]
Efomycine M	DMOKX76	Discovery agent	N.A.	Investigative	[23]
1na	DM0A1YI	Discovery agent	N.A.	Investigative	[14]

Drug(s) Targeting Liver carboxylesterase (CES1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[14]
PACTIMIBE	DM0NZDT	Arteriosclerosis	BD40	Phase 2/3	[24]
K-604	DMQVN6P	Arteriosclerosis	BD40	Phase 2	[25]
Eldacimibe	DML7WP0	Hyperlipidaemia	5C80	Phase 2	[26]
GR148672X	DM7W6YN	Acute lymphoblastic leukaemia	2A85	Clinical trial	[27]
Avasimibe	DMFG4OM	Peripheral vascular disease	BD4Z	Discontinued in Phase 3	[28]
E-5324	DM562BM	Hyperlipidaemia	5C80	Discontinued in Phase 2	[29]
RP-64477	DMTQ3BS	Hyperlipidaemia	5C80	Discontinued in Phase 2	[30]
CI-976	DMBO28J	Hyperlipidaemia	5C80	Discontinued in Phase 2	[31]
CL-283796	DM7LIDT	Hyperlipidaemia	5C80	Discontinued in Phase 2	[32]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
E-selectin (SELE)	TTAU4D6	LYAM2_HUMAN	Inhibitor	[1]
Influenza Neuraminidase (Influ NA)	TT50QJ3	NRAM_I33A0	Inhibitor	[1]
Liver carboxylesterase (CES1)	TTMF541	EST1_HUMAN	Inhibitor	[1]
P-selectin (SELP)	TTE5VG0	LYAM3_HUMAN	Inhibitor	[1]

References

• [1] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [2] Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84.
• [3] Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
• [4] Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics. Expert Opin Biol Ther. 2022 Nov;22(11):1417-1428.
• [5] Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
• [6] Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
• [7] Clinical pipeline report, company report or official report of Selexys Pharmaceuticals (2011).
• [8] rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6.
• [9] Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007.
• [10] WO patent application no. 2001,0276,21, Competitive inhibition elisa for antibody detection.
• [11] Administration of an antibody to E-selectin in patients with septic shock. Crit Care Med. 1996 Feb;24(2):229-33.
• [12] Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102.
• [13] Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13.
• [14] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [15] Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009 Nov 6;4(11):e7838.
• [16] US patent application no. 2010,0081,713, Compositions and methods for treating viral infections.
• [17] CN patent application no. 104447481, Benzoic acid thiourea anti-influenza virus compounds as well as preparation method and use thereof.
• [18] Clinical pipeline report, company report or official report of glycomimetics.
• [19] Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia. Shock. 2008 Apr;29(4):475-82.
• [20] Clinical pipeline report, company report or official report of GlycoMimetics.
• [21] ClinicalTrials.gov (NCT04255875) A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED EVALUATION OF SINGLE DOSES OF PF-07209326 IN HEALTHY PARTICIPANTS (SAFETY, TOLERABILITY, AND PHARMACOKINETICS [PK]) FOLLOWED BY AN OPEN LABEL, REPEAT DOSE EVALUATION IN SICKLE CELL DISEASE PARTICIPANTS (SAFETY, TOLERABILITY, PK AND EFFICACY). U.S.National Institutes of Health.
• [22] Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96.
• [23] Interfering with leukocyte rolling--a promising therapeutic approach in inflammatory skin disorders Trends Pharmacol Sci. 2003 Feb;24(2):49-52.
• [24] Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and b... J Med Chem. 2008 Aug 14;51(15):4823-33.
• [25] A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis. 2007 Apr;191(2):290-7.
• [26] Prospects for drug therapy for hyperlipoproteinaemia. Diabete Metab. 1995 Apr;21(2):139-46.
• [27] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592).
• [28] New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology. 2002;97(2):59-66.
• [29] Effect of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbits. Atherosclerosis. 1994 Jun;107(2):187-201.
• [30] RP 64477: a potent inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase with low systemic bioavailability. Biochem Pharmacol. 1996 Feb 23;51(4):413-21.
• [31] Acyl-coenzyme A:cholesterol-acyltransferase (ACAT) inhibitors modulate monocyte adhesion to aortic endothelial cells. Atherosclerosis. 1995 Jan 6;112(1):7-17.
• [32] ACAT inhibitors CL 283,546 and CL 283,796 reduce LDL cholesterol without affecting cholesterol absorption in African green monkeys. J Lipid Res. 1995 Jun;36(6):1199-210.